by Heather Slowik and Stephen Levin
Trying to make sense of the new Medicare legislation is truly a Sisyphusian task. For starters, it's 1,100 pages long...
After decades of public policy debate, the passage of a prescription drug benefit for seniors-Medicare Part D-hardly settles the issue. Indeed, the heavy lifting really begins now because the recently enacted legislation represents a model drawn more in sand than stone. So there is plenty of time and opportunity for all parties to continue to shape this program more to their liking. For the moment, we do know that seniors are slated for drug coverage beginning in 2006 and price controls are off the table. But there are still major questions concerning the implementation. Looming over the whole debate: the specter of rising costs. The Congressional Budget Office's $400 billion prediction-for the ten years spanning 2004 to 2013-has already been characterized as too low. Bush administration aides estimates that the figure should be closer to $540 billion. Given all this uncertainty, the drug industry should be prepared for rough Medicare seas in the foreseeable future.
by Heather Slowik and Stephen Levin
Trying to make sense of the new Medicare legislation is truly a Sisyphusian task. For starters, it's 1,100 pages long...
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.